This study is designed to test an adaptive pharmacotherapy algorithm within the Duke Smoking Cessation Program (DSCP). The investigators hypothesize that patients treated in the DSCP with Algorithm-based pharmacotherapy vs. Varenicline will show significantly higher 12-week post-quit 30-day continuous abstinence.